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Background: Metabolic surgery is associated with a prompt improvement in insulin resistance, although
the mechanism of action remains unknown. The literature on bile acid changes after metabolic surgery
is conflicting, and insulin sensitivity is generally assessed by indirect methods. The aim of this study was
to investigate the relationship between improvement in insulin sensitivity and concentration of circulating
bile acids after biliopancreatic diversion (BPD) and Roux-en-Y gastric bypass (RYGB).
Methods: This was a prospective observational study of nine patients who underwent BPD and six who
had RYGB. Inclusion criteria for participation were a BMI in excess of 40 kg/m2, no previous diagnosis
of type 2 diabetes and willingness to participate. Exclusion criteria were major endocrine diseases,
malignancies and liver cirrhosis. Follow-up visits were carried out after a mean(s.d.) of 185⋅3(72⋅9)
days. Fasting plasma bile acids were assessed by ultra-high-performance liquid chromatography coupled
with a triple quadrupole mass spectrometer, and insulin sensitivity was measured by means of a
hyperinsulinaemic–euglycaemic clamp.
Results: A significant increase in all bile acids, as well as an amelioration of insulin sensitivity, was
observed after metabolic surgery. An increase in conjugated secondary bile acids was significantly asso-
ciated with an increase in insulin sensitivity. Only the increase in glycodeoxycholic acid was significantly
associated with an increase in insulin sensitivity in analysis of individual conjugated secondary bile acids.
Conclusion: Glycodeoxycholic acid might drive the improved insulin sensitivity after metabolic surgery.
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Introduction
Bariatric surgery is the only currently available obesity
treatment resulting in long-term weight loss1. Several
studies2–4 have shown remission of type 2 diabetes and
improvements in insulin resistance long before weight
reduction, and this has led to introduction of the term
metabolic surgery. The mechanism behind the rapid
improvement in insulin resistance remains unclear.
Bile acids bind to the farnesoid X receptor (FXR) and
to the G-protein-coupled bile acid receptor (TGR5), two
receptors whose activation mediates effects on energy and
glucose homeostasis5. The primary bile acids, cholic acid
(CA) and chenodeoxycholic acid (CDCA), are produced
by hepatocytes and conjugated with glycine or taurine to
form conjugated bile acids before secretion into the small
intestine. A large portion of the conjugated bile acids is
reabsorbed in the terminal ileum, and a smaller portion
is converted to secondary bile acids in the large intestine
by the gut microbiota and then reabsorbed or lost with
stool6. Some types of metabolic surgery lead to a reduced
gastric volume combined with bypassing parts of the small
intestine, thus leading to a more rapid delivery of nutrients
into the jejunum or ileum, and bile coming in contact
with the nutrients more distally in the intestine. Higher
levels of bile acids have been reported in patients after
Roux-en-Y gastric bypass (RYGB)7, and patients who have
undergone bariatric surgery display changes in the gut
microbial composition8 known to metabolize bile acids9.
Interestingly, in two knock-out mice models, one lacking
the nuclear FXR, which binds bile acids, and the other
missing the cell membrane TGR5, activated by bile acids,
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improvement in insulin sensitivity after metabolic surgery
was attenuated or absent10,11. Hence, bile acids may play a
primary role in the amelioration of insulin sensitivity that
follows metabolic surgery.
A major drawback in previous studies is that insulin
sensitivity was measured by indirect methods. The
hyperinsulinaemic–euglycaemic clamp is considered
the standard method. The aim of the present study was
to investigate, by use of the clamp technique, whether
changes in insulin sensitivity are related to changes in
plasma levels of bile acids, in patients who have undergone
biliopancreatic diversion (BPD) or RYGB.
Methods
Study protocols were approved by the regional ethics com-
mittee at the Catholic University Hospital of the Sacred
Heart, Rome, Italy. All participants gave written informed
consent to take part in the study.
Study participants
Patients were recruited at the obesity centre at the Catholic
University Hospital of the Sacred Heart, Rome, Italy. The
patients underwent either RYGB or BPD for treatment
of obesity. No randomization to the different surgical treat-
ments was undertaken. Inclusion criteria for participating
in the study were a BMI greater than 40 kg/m2, no previ-
ous diagnosis of type 2 diabetes, with glycated haemoglobin
(HbA1c) 7 per cent or less, and willingness to be included in
the study. Exclusion criteria were major endocrine diseases,
malignancies and liver cirrhosis.
At inclusion and follow-up, blood samples were obtained
from patients after overnight fasting and anthropometric
data were collected. Blood chemistry analysis was under-
taken at the central laboratory of the Catholic University
Hospital of the Sacred Heart, Rome.
Hyperinsulinaemic–euglycaemic clamp
Study participants were fasted overnight and under-
went a hyperinsulinaemic–euglycaemic clamp to assess
peripheral insulin sensitivity12. On the morning of the
test, venous access was established into the antecubital
vein for infusions. A second access was inserted into a
hand vein and the hand was placed in a heated air box
(60∘C) to obtain arterialized blood samples. The patients
received a primed constant insulin infusion (6 pmol
per min per kg) and a variable glucose infusion, which
was adjusted so that blood glucose concentration was
clamped at the fasting value for 2 h. Adjustment of the
variable glucose infusion was undertaken every 5 min
when needed on the basis of blood glucose measurements.
Whole-body glucose uptake (M) was calculated during the
last 40 min of clamping during steady-state euglycaemic
hyperinsulinaemia.
Measurement of fasting bile acids
A targeted platform based on ultra-high-performance
liquid chromatography coupled with a triple quadrupole
mass spectrometer was applied to quantify fasting bile acids
in both unconjugated and conjugated forms, as described
previously13. Briefly, 4 μl of bile acid internal standard
(IS) mixture was added to 20 μl of plasma. The IS mixture
contained the following compounds (each at a con-
centration of 50 ng/ml): CA, CDCA, deoxycholic acid
(DCA), lithocholic acid (LCA), ursodeoxycholic acid
(UDCA), glycocholic acid (GCA), glycochenodeoxycholic
acid (GCDCA), glycodeoxycholic acid (GDCA), glyco-
lithocholic acid (GLCA), glycoursodeoxycholic acid
(GUDCA), taurocholic acid, taurochenodeoxycholic acid
(TCDCA), taurodeoxycholic acid and the deuterated
forms (CA-d4, CDCA-d4, DCA-d4, LCA-d4, UDCA-d4,
GCA-d4, GUDCA-d4, GCDCA-d4, GLCA-d4). The
bile acids were obtained from Sigma-Aldrich (St Louis,
Missouri, USA) and the deuterated forms of bile acids
from QMx Laboratories (Thaxted, UK). Precipitation of
proteins was carried out by adding 24 μl of acetonitrile.
The samples were then vortexed for 5 s and underwent
3 min of ultrasound treatment before being centrifuged
for 5 min at 12 100 g. Evaporation of the samples was per-
formed with nitrogen, and they were then reconstituted
with 4 μl of methanol and further diluted with 6 μl of water.
Analysis of the samples was undertaken on this solution
but also on a further dilution with methanol (1 to 20).
An Acquity ultra-high-performance liquid chromatog-
raphy system (Milford, Massachusetts, USA) and Xevo
triple quadrupole mass spectrometer (Waters, Manchester,
UK) were used for bile acid analysis. An Acquity HSS
T3 (2⋅1 Å∼100 mm, 1⋅7 μm) column (Waters) kept at
35∘C was used for chromatography. A volume of 3 μl was
injected. A gradient elution with 0⋅1 per cent formic acid
in water (v/v) (A) and 0⋅1 per cent formic acid in acetoni-
trile : methanol (3 : 1, v/v) (B) at a flow rate of 0⋅5 ml/min
was used for separation. The gradient programme was set
to: 0 min 15 per cent B, 1 min 30 per cent B, 16 min 70
per cent B, 18–20 min 100 per cent B. The equilibrium
time was 5 min between runs. A negative polarity with
2⋅0 kV capillary voltage was used when mass spectrometry
was carried out. A desolvation temperature of 650∘C and
a source temperature of 150∘C were applied together
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Table 1 Patient characteristics
Before intervention After intervention
All (n = 15) BPD (n = 9) RYGB (n = 6) All (n = 15) BPD (n = 9) RYGB (n = 6)
Age (years) 44⋅3(8⋅3) 44⋅7(8⋅1) 43⋅7(9⋅4) 44⋅8(8⋅4) 45⋅1(8⋅3) 44⋅3(9⋅4)
Sex ratio (M : F) 10 : 5 4 : 5 6 : 0¶ 10 : 5 4 : 5 6 : 0¶
Height (cm) 171⋅5(9⋅2) 167⋅3(9⋅1) 177⋅8(5⋅1)§ 171⋅3(9⋅2) 167⋅0(8⋅9) 177⋅8(5⋅1)§
BMI (kg/m2) 51⋅6(9⋅6) 55⋅8(9⋅5) 45⋅3(5⋅7)§ 37⋅7(7⋅4)* 39⋅1(8⋅5)† 35⋅5(5⋅5)‡
Weight (kg) 151⋅0(24⋅8) 156⋅3(28⋅7) 143⋅0(16⋅7) 110⋅4(22⋅2)* 109⋅4(26⋅8)† 112⋅0(15⋅1)‡
Interval to follow-up (days) 185⋅3(72⋅9) 183⋅7(61⋅8) 187⋅8(93⋅6)
Weight loss (kg) –40⋅6(19⋅4) –46⋅9(21⋅8) –31⋅0(10⋅78)
Weight loss (%) –27(11) –30(12) –22(7)
Plasma glucose (mg/dl) 97⋅5(17⋅0) 101⋅7(20⋅7) 91⋅3(6⋅3) 76⋅8(11⋅1)* 76⋅7(13⋅8)‡ 77⋅0(6⋅3)‡
HbA1c (%) 5⋅9(0⋅36) 6⋅0(0⋅38) 5⋅8(0⋅33) 5⋅5(0⋅21)† 5⋅6(0⋅22)‡ 5⋅4(0⋅19)‡
HbA1c (mmol/mol) 41⋅4(3⋅7) 42⋅1(4⋅0) 40⋅3(3⋅3) 36⋅5(2⋅6)† 37⋅3(2⋅5)‡ 35⋅3(2⋅3)‡
M (mg per kg per min) 2⋅71(1⋅45) 2⋅34(1⋅21) 3⋅27(1⋅70) 5⋅95(2⋅21)* 6⋅09(2⋅29)‡ 5⋅74(2⋅28)‡
Type 2 diabetes 2 1 1 0 0 0
Total cholesterol (mg/dl) 189⋅6(28⋅2) 197⋅0(31⋅3) 178⋅5(20⋅2) 138⋅1(28⋅6)† 124⋅7(17⋅3)†§ 158⋅2(31⋅7)§
HDL cholesterol (mg/dl) 47⋅1(9⋅5) 47⋅9(7⋅9) 46⋅0(12⋅4) 41⋅7(12⋅3) 38⋅9(13⋅2) 45⋅5(11⋅0)
LDL cholesterol (mg/dl) 119⋅5(22⋅1) 127⋅9(16⋅3) 107⋅8(25⋅6) 74⋅9(27⋅5)† 61⋅6(14⋅2)‡§ 92⋅7(32⋅0)§
Triglycerides (mg/dl) 134⋅9(58⋅5) 141⋅4(52⋅7) 126⋅3(69⋅7) 109⋅6(49⋅3) 116⋅2(61⋅1) 99⋅7(25⋅2)
AST (units/l) 35⋅3(21⋅0) 34⋅5(25⋅6) 36⋅6(13⋅2) 29⋅8(18⋅1) 28⋅1(11⋅4) 31⋅8(25⋅0)
ALT (units/l) 45⋅7(37⋅4) 48⋅6(48⋅1) 41⋅8(19⋅3) 37⋅5(27⋅7) 39⋅3(24⋅7) 34⋅6(35⋅0)
Values are mean(s.d.) for continuous variables. BPD, biliopancreatic diversion; RYGB, Roux-en-Y gastric bypass; HbA1c, glycated haemoglobin; M,
whole-body glucose uptake; HDL, high-density lipoprotein; LDL, low-density lipoprotein; AST, aspartate aminotransferase; ALT, alanine aminotrans-
ferase. *P < 0⋅001, †P < 0⋅010, ‡P < 0⋅050 versus same patient group before operation (Wilcoxon signed-rank test); §P < 0⋅050 versus BPD at the same time
point (Mann–Whitney U test); ¶P < 0⋅050 versus BPD at the same time point (Fisher’s exact test).
with the following gas flow settings: cone gas flow 150 l/h
(nitrogen), desolvation gas 1100 l/h (nitrogen), collision
gas 0⋅15 ml/min (argon). A selected reaction monitor
with auto dwell time function (dwell time 20–95 ms, 20
points/peak) was used to detect the analytes. A calibration
curve from 1⋅4 pg/ml to 642 ng/ml with a series of 1 : 3
dilutions was used. The IS method was applied to quantify
the analytes.
Statistical analysis
Continuous data are presented as mean(s.d.). Wilcoxon
signed-rank test was used to compare differences between
baseline and follow-up after each procedure. The
Mann–Whitney U test was used for comparisons of
continuous variables between the different surgery groups
at each time point. Fisher’s exact test was used for com-
parisons of categorical variables between patients who
underwent BPD and RYGB at the same time point. A
principal component analysis and a heat map cluster-
ing analysis were carried out on bile acid data before
and after intervention, and log2 values were calculated.
Spearman correlation analysis was undertaken between
fold changes of bile acids (after versus before intervention)
and fold changes in M (after versus before intervention)
to select variables for further linear regression analysis.
Before linear regression analysis, log2 values of the fold
changes were calculated to achieve linear relationships.
P < 0⋅050 was considered statistically significant. Principal
component analysis and clustering analysis with heat map
construction were carried out with MetaboAnalyst (https://
www.metaboanalyst.ca/)14. Other statistical analyses were
undertaken with SPSS® version 21.0 (IBM, Armonk, New
York, USA).
Results
Fifteen patients were included in the study who unde-
rwent either RYGB (6) or BPD (9) for treatment of obe-
sity. Follow-up visits were carried out after a mean(s.d.)
of 185⋅3(72⋅9) days.
Patient characteristics before and after metabolic surgery
are presented in Table 1. A significantly higher propor-
tion of men were present in the RYGB group (6 of 6)
compared with the BPD group (4 of 9; P = 0⋅044), and
the RYGB group was also significantly taller (177⋅8(5⋅1)
versus 167⋅3(9⋅1) cm; P = 0⋅018). The BPD group had a
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 1178–1186
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Table 2 Bile acid levels before and after surgery
Before intervention After intervention
All BPD RYGB All BPD RYGB
Reference values
from Schmid et al.15
Primary bile acids 0⋅89(0⋅39) 0⋅98(0⋅42) 0⋅75(0⋅31) 5⋅14(2⋅09)† 4⋅70(1⋅71)† 5⋅81(2⋅59)‡ –
CA (μmol/l) 0⋅09(0⋅08) 0⋅09(0⋅09) 0⋅09(0⋅08) 1⋅43(1⋅01)* 1⋅10(0⋅73)† 1⋅93(1⋅23)‡ 0⋅87(0⋅20)
GCA (μmol/l) 0⋅21(0⋅09) 0⋅23(0⋅09) 0⋅18(0⋅10) 0⋅90(0⋅48)* 0⋅76(0⋅47)† 1⋅11(0⋅44)‡ 0⋅32(0⋅53)
TCA (μmol/l) 0⋅04(0⋅02) 0⋅04(0⋅02) 0⋅04(0⋅02) 0⋅11(0⋅04)* 0⋅11(0⋅05)† 0⋅12(0⋅04)‡ 0⋅07(0⋅01)
CDCA (μmol/l) 0⋅12(0⋅03) 0⋅12(0⋅3) 0⋅13(0⋅02) 1⋅31(0⋅86)* 1⋅19(0⋅58)† 1⋅50(1⋅20)‡ 0⋅57(0⋅13)
GCDCA (μmol/l) 0⋅18(0⋅08) 0⋅19(0⋅07) 0⋅17(0⋅10) 1⋅03(0⋅71)* 1⋅19(0⋅83)† 0⋅78(0⋅41)‡ 0⋅74(0⋅09)
TCDCA (μmol/l) 0⋅24(0⋅23) 0⋅30(0⋅28) 0⋅14(0⋅08) 0⋅35(0⋅24)† 0⋅34(0⋅27) 0⋅37(0⋅22)‡ 0⋅19(0⋅02)
Secondary bile acids 0⋅79(0⋅60) 0⋅70(0⋅68) 0⋅93(0⋅47) 2⋅56(0⋅70)† 2⋅58(0⋅58)† 2⋅52(0⋅90)‡ –
DCA (μmol/l) 0⋅55(0⋅46) 0⋅47(0⋅49) 0⋅67(0⋅43) 1⋅37(0⋅73)† 1⋅43(0⋅83)‡ 1⋅28(0⋅60)‡ 0⋅40(0⋅37)
GDCA (μmol/l) 0⋅19(0⋅16) 0⋅16(0⋅18) 0⋅22(0⋅14) 0⋅89(0⋅35)* 0⋅84(0⋅35)‡ 0⋅96(0⋅38)‡ 0⋅35(0⋅05)
TDCA (μmol/l) 0⋅05(0⋅07) 0⋅05(0⋅09) 0⋅03(0⋅04) 0⋅17(0⋅08)* 0⋅18(0⋅10)† 0⋅16(0⋅07)‡ 0⋅08(0⋅01)
GLCA (μmol/l) 0⋅01(0⋅00) 0⋅01(0⋅00) 0⋅01(0⋅00) 0⋅13(0⋅07)* 0⋅13(0⋅07)† 0⋅11(0⋅07)‡ 0⋅16(0⋅03)
Tertiary bile acids
GUDCA (μmol/l) 0⋅03(0⋅02) 0⋅03(0⋅02) 0⋅02(0⋅01) 0⋅14(0⋅09)* 0⋅13(0⋅09)† 0⋅14(0⋅09)‡ 0⋅13(0⋅03)
Secondary : primary ratio 0⋅99(0⋅89) 0⋅66(0⋅67) 1⋅48(1⋅01) 0⋅59(0⋅30) 0⋅64(0⋅32) 0⋅50(0⋅26) –
Conjugated : unconjugated ratio 2⋅40(2⋅35) 3⋅13(2⋅73) 1⋅31(1⋅10) 1⋅20(0⋅85) 1⋅34(1⋅01) 0⋅99(0⋅56) –
Values are mean(s.d.). BPD, biliopancreatic diversion; RYGB, Roux-en-Y gastric bypass; CA, cholic acid; GCA, glycocholic acid; TCA, taurocholic
acid; CDCA, chenodeoxycholic acid; GCDCA, glycochenodeoxycholic acid; TCDCA, taurochenodeoxycholic acid; DCA, deoxycholic acid; GDCA,
glycodeoxycholic acid; TDCA, taurodeoxycholic acid; GLCA, glycolithocholic acid; GUDCA, glycoursodeoxycholic acid. *P < 0⋅001, †P < 0⋅010,
‡P < 0⋅050 versus same patient group before operation (Wilcoxon signed-rank test).
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a Score plot of the two principal components from the principal component analysis. b Heat map with clustering analysis on autoscaled features. POST,
after surgery; PRE, before surgery; TCDCA, taurochenodeoxycholic acid; TCA, taurocholic acid; GUDCA, glycoursodeoxycholic acid; GCA, glycocholic
acid; GCDCA, glycochenodeoxycholic acid; DCA, deoxycholic acid; GLCA, glycolithocholic acid; CA, cholic acid; CDCA, chenodeoxycholic acid; GDCA,
glycodeoxycholic acid; TDCA, taurodeoxycholic acid.
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c  M versus GDCA
Scatter plot of log2 fold change of whole-body glucose uptake (M) versus a log2 fold change of secondary bile acids (y = 0⋅564+ 0⋅242x; r2 = 0⋅535), b log2
fold change of secondary conjugated bile acids (y = 0⋅427+ 0⋅243x; r2 = 0⋅465) and c glycodeoxycholic acid (GDCA) (y = 0⋅660+ 0⋅154x; r2 = 0⋅336).
significantly higher BMI than the RYBG group (55⋅8(9⋅5)
versus 45⋅3(5⋅7) kg/m2; P = 0⋅034).
Improvement in insulin sensitivity and metabolic
parameters after metabolic surgery
Several metabolic parameters, including BMI, fasting
plasma glucose concentration, HbA1c and M, were
significantly improved after RYGB and BPD (Table 1).
A significant reduction in serum concentrations of total
cholesterol and low-density lipoprotein cholesterol was
observed after BPD, but not after RYGB, when the
two groups were analysed separately (Table 1). However,
no significant difference in percentage weight loss was
observed between patients who underwent BPD and those
who had RYGB (30(12) and 22(7) per cent respectively;
P = 0⋅224).
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 1178–1186
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Fasting plasma levels of bile acids are increased
after metabolic surgery
Data on levels of bile acids before and after metabolic
surgery are presented together with reference data15 from
a mixed population in Table 2. All bile acid concentrations
were significantly increased after metabolic surgery when
the two surgery groups were analysed together (Table 2).
This was also seen in separate analyses for the two surgery
groups, except for TCDCA in the BPD group where the
increase after surgery was not statistically significant. In
addition, a good separation of bile acids for before versus
after surgery was observed in the principal component
analysis, with two factors explaining 15⋅4 and 60⋅6 per
cent of the variance respectively (Fig. 1a). A heat map
construction with a hierarchical cluster analysis of plasma
bile acid levels was also able to separate between before and
after surgery (Fig. 1b).
No differences in individual fasting bile acid levels were
observed between the RYGB and BPD groups, before
or after the intervention. In addition, no differences in
the ratios of conjugated : unconjugated bile acids and sec-
ondary : primary bile acids were observed, when the surgery
groups were analysed together or separately (Table 2).
Changes in bile acid levels are associated with,
and can predict, changes in insulin sensitivity
The change in all secondary bile acid levels correlated pos-
itively with the change in M (ρ = 0⋅801, P < 0⋅001). When
the secondary bile acids were divided into groups of con-
jugated and unconjugated bile acids, both the increase in
DCA (ρ = 0⋅678, P = 0⋅008) and the increase in conjugated
secondary bile acids (ρ = 0⋅592, P = 0⋅020) correlated pos-
itively with the increase in M. However, when the changes
in individual bile acid concentrations were analysed, only
the change in GDCA showed a positive correlation with
the change in M (ρ = 0⋅663, P = 0⋅007).
Linear regression analysis revealed that the changes in
concentrations of secondary bile acids (Fig. 2a), secondary
conjugated bile acids (Fig. 2b) and GDCA (Fig. 2c), but not
DCA, could predict the change in M. The increase in the
secondary bile acids accounted for 53⋅5 per cent of the
variation in the change of M, and could statistically pre-
dict the change in M with the formula: log2 fold change
in M = 0⋅564+ (0⋅242× log2 fold change in secondary bile
acids) (P = 0⋅002). Analysis of only the change in conju-
gated secondary bile acids showed that they accounted for
46⋅5 per cent of the variability in the change of M and
could statistically predict the change in M with the for-
mula: log2 fold change in M = 0⋅427+ (0⋅243× log2 fold
change in secondary conjugated bile acids) (P = 0⋅005). In
addition, the individual increase in GDCA accounted for
33⋅6 per cent of the variation in change of M and the change
in GDCA could statistically predict the change in M with
the formula: log2 fold change in M = 0⋅660+ (0⋅154× log2
fold change in GDCA) (P= 0⋅023).
Discussion
The present results showed that plasma levels of total bile
acids were increased after both BPD and RYGB surgery,
with a marked improvement in insulin sensitivity. The
improvement in insulin sensitivity after metabolic surgery
was closely associated with, and predicted by, the increases
in secondary conjugated bile acids, particularly GDCA.
The results, moreover, showed an increase in fasting cir-
culating levels of both primary and secondary bile acids
and almost all individual bile acids after BPD and RYGB.
These results are in line with some previous studies16–18
showing increases in total fasting bile acid concentra-
tions after RYGB and BPD. A previous study19, however,
reported an early decrease in total bile acid levels after
RYGB, whereas some metabolic procedures, such as band-
ing and sleeve gastrectomy, did not appear to affect total
bile acid levels20–22. The studies22,23 of subgroups or indi-
vidual bile acids after metabolic surgery displayed more
diverse results. Concentrations of primary conjugated bile
acids and CA decreased, and only the secondary bile acids
and mainly GUDCA increased after sleeve gastrectomy22,
whereas Werling and colleagues23 showed that the levels of
unconjugated bile acids and glycine-conjugated bile acids
increased, and mainly GLCA decreased, after RYGB. The
results of the present study, however, indicated that the lev-
els of almost all fasting circulating bile acids increased after
two types of metabolic surgery, RYGB and BPD.
Recent studies24,25 concluded that several different
mechanisms, such as weight loss, calorie restriction and
rerouting of nutrients, may contribute to improvement
in insulin sensitivity after metabolic surgery. The present
study demonstrated that the change in concentration of
secondary conjugated bile acids, and especially GDCA,
was associated with positive changes in M after metabolic
surgery. Some associations between bile acids and insulin
sensitivity have been reported previously. Ferrannini and
co-workers26 showed a significant correlation between
the ratio of unconjugated : conjugated bile acids and M
after BPD. Interestingly, an alternative hypothesis, with
insulin resistance driving the production of bile acids, was
suggested after a positive correlation was found between
12-α-hydroxylated bile acids and the homeostatic model
assessment for insulin resistance27. In some studies of
bile acids and metabolic surgery16,19,20, however, no links
© 2019 The Authors. BJS published by John Wiley & Sons Ltd www.bjs.co.uk BJS 2019; 106: 1178–1186
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between changes in bile acids and insulin sensitivity were
found. Hence, the effect of bile acid changes on insulin
sensitivity after metabolic surgery is still unclear, but
the present results suggest a potential role of conju-
gated secondary bile acids in the amelioration of insulin
sensitivity.
The two main bile acid receptors mediating the possi-
ble metabolic effects are FXR and TGR55. Mice lacking
FXR or TGR5 display attenuated or absent improvement
in insulin sensitivity after metabolic surgery, indicating a
possible role for these receptors in the improved insulin
sensitivity seen after metabolic surgery10,11. FXR is usually
activated by primary bile acids and TGR5 by secondary
bile acids6. Activation of human TGR5 has been shown
to be dose-dependent in Chinese hamster ovary cells and
human embryonic kidney 293 cells, and different bile acids
are known to have different ability to activate the receptor,
with LCA the strongest, followed by DCA, CDCA, then
CA28,29. The opposite pattern has been observed for FXR
where CDCA is the most potent activator followed by CA,
DCA and LCA, whereas UCDCA is considered a partial
agonist30–33. However, during a clamp, M is, to a large
extent, based on the glucose uptake in muscle tissue, as 75
per cent of glucose during the clamp is taken up by mus-
cles and not by the liver. Interestingly, TGR5 is expressed
in skeletal muscle28, whereas expression of FXR has not
been reported in human muscle tissue, but it has in liver
and colon6,34. In human muscle tissue, activation of TGR5
is known to lead to increased energy expenditure by conver-
sion of thyroxine T4 into the active tri-iodothyronine T335,
possibly resulting in increased insulin sensitivity. Another
possible explanation for the present findings is that more
bile acids reach the colon after metabolic surgery, and
that TGR5 activation in enteroendocrine cells increases
glucagon-like peptide 1 release, which mediates glucose
uptake in muscle36–38. Taken together, if secondary con-
jugated bile acids play a role in the amelioration of insulin
sensitivity, this could be mediated via the TGR5 receptor,
which might explain why only the secondary conjugated
bile acids were associated with M in the present study.
Metabolic surgery procedures in which the bile is
diverted distally in the ileum, such as BPD, should modify
the bile acid pool to a greater extent than less malabsorp-
tive procedures, such as RYGB, where the bile is diverted
into the proximal jejunum. Differences in circulating bile
acid levels between BPD and RYGB have been reported
in humans16 but BPD and RYGB groups in the present
study showed remarkably similar fasting bile acid levels
and profiles. Interestingly, a previous study39 in the rat
suggested that bile diversion in the mid-jejunum and in
the mid-ileum led to the same level of plasma bile acids
and improvement in glucose tolerance, which supports
the present results and suggests that the length of the
alimentary limb does not have a major role in determining
the increased bile acid levels after metabolic surgery. It
was not possible to rule out differences in the postprandial
bile acid levels into the present study. In addition, systemic
circulating bile acids are not a complete reflection of com-
position changes in the enterohepatic circulation, which
may differ between the two surgical procedures.
The present study has limitations. Follow-up visits were
carried out a mean(s.d.) of 185⋅3(72⋅9) days after surgery,
when the patients had achieved substantial weight loss
(mean(s.d.) –40⋅6(19⋅4) kg). Hence, this study did not cap-
ture the relationship between bile acids and the immediate
metabolic effect after metabolic surgery before weight loss
had occurred. Other mechanisms, such as calorie restri-
ction and weight loss, may also contribute to the amelior-
ation of insulin sensitivity.
Patients undergoing metabolic surgery show an improve-
ment in insulin sensitivity in parallel with a marked increase
in bile acids. Changes in concentrations of secondary con-
jugated bile acids as a group, and particularly GDCA, were
associated with improvement in insulin sensitivity, suggest-
ing a potential role in insulin sensitivity improvement after
metabolic surgery.
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